
Zimmer Biomet's Q2 Sales Rise 7% to $2.1B Despite Earnings Drop from Acquisitions
Zimmer Biomet Holdings, Inc.Description
What this story covers
Zimmer Biomet reported Q2 net sales of $2.1 billion, up 7% YoY, driven by Paragon 28 acquisition and organic growth in orthopedics. However, net earnings fell to $153 million due to integration costs, inflation, and higher debt interest. Full-year sales outlook: 6.7-7.7% growth; earnings expected lower amid tariffs and taxes. Strong liquidity supports ongoing strategies.
Story snapshot
CompanyZimmer Biomet Holdings, Inc.
TickerZBH
VariantStandard detailed
Duration13:04
Filing type10-Q
PeriodQ2 2025
IndustryHealthcare & Pharmaceuticals
Accession0000950170-25-104989
Full Story Script
Content not available for this story.